1055303-62-2

Upstream product

• 236736-23-5 2-phenyl-5-(trifluoromethyl)oxazole-4-carboxylic acid 

Downstream Products

• 1055303-82-6 4-[2-[2-(4-fluoro-phenyl)-ethylsulfanyl]-2-(2,2,2-trichloro-ethoxycarbonyl)-ethyl]-benzoic acid 2-phenyl-5-trifluoromethyl-oxazol-4-ylmethyl ester 
• 1107663-02-4 4-(Chloromethyl)-2-phenyl-5-(trifluoromethyl)-1,3-oxazole 
• 1593269-55-6 4-(bromomethyl)-2-phenyl-5-(trifluoromethyl)-1,3-oxazole 
• 1593269-71-6 tert-butyl 2-(4-{[{[2-phenyl-5-(trifluoromethyl)-1,3-oxazol-4-yl] methyl}(furan-2-ylmethyl) amino] methyl}-2,6-dimethylphenoxy)-2-methylpropanoate 
• 1593269-83-0 2-(4-{[{[2-phenyl-5-(trifluoromethyl)-1,3-oxazol-4-yl]-methyl}(furan-2-ylmethyl) amino] methyl}-2,6-dimethylphenoxy)-2-methylpropanoic acid 
• 1055303-24-6 4-{2-carboxy-2-[2-(4-fluoro-phenyl)-ethylsulfanyl]-ethyl}-benzoic acid 2-phenyl-5-trifluoromethyl-oxazol-4-ylmethyl ester 
• 1262620-74-5 3-(difluoro{[2-phenyl-5-(trifluoromethyl)-1,3-oxazol-4-yl]methoxy}methyl)-6-[4-(trifluoromethoxy)phenyl][1,2,4]triazolo[4,3-a]pyridine 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of novel zwitterionic compounds as peroxisome proliferator activated receptor α/γ dual agonists with improved physicochemical properties

We describe herein the design, syntheses and structure-activity relationships (SAR) of novel zwitter-ionic compounds as non-thiazolidinedion (TZD) based peroxisome proliferator activated receptor (PPAR) α/γ dual agonists. In the previous report, we obtained compound 1 showing potent PPARα/γ dual agonistic activities, together with a great glucose lowering effect in the db/db mice. However, this compound possessed fatal issues such as potent cytochrome P450 (CYP)3A4 direct inhibitory activity. Thus, we carried out the medicinal optimization to improve these while maintaining the potent PPAR agonistic activity. As a result, the issues were addressed by changing the furan ring to a low lipophilic 1,3,4-oxadiazole ring. Additionally, these oxadiazole derivatives exhibited a significant decrease in plasma glucose and plasma triglyceride levels without marked weight gain.

SUBSTITUTED ARYLOXAZOLES AND THEIR USE

The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and metabolic disorders.

2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl) propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl) propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methylor ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them.